Vigil Neuroscience (VIGL)
(Delayed Data from NSDQ)
$3.68 USD
-0.07 (-1.87%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $3.70 +0.02 (0.54%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Income Statements
Fiscal Year end for Vigil Neuroscience, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 0 | 0 | 0 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 89 | 69 | 42 | 27 | 0 |
Income After Depreciation & Amortization | -89 | -69 | -42 | -27 | 0 |
Non-Operating Income | 6 | 1 | -1 | -1 | NA |
Interest Expense | 0 | 0 | 0 | 0 | NA |
Pretax Income | -83 | -68 | -43 | -29 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -83 | -68 | -43 | -29 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -83 | -68 | -43 | -29 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -90 | -69 | -42 | -27 | 0 |
Depreciation & Amortization (Cash Flow) | -1 | 0 | 0 | 0 | NA |
Income After Depreciation & Amortization | -89 | -69 | -42 | -27 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 38.71 | 31.69 | 1.53 | NA | NA |
Diluted EPS Before Non-Recurring Items | -2.13 | -2.16 | -28.26 | NA | NA |
Diluted Net EPS (GAAP) | -2.13 | -2.16 | -28.26 | NA | NA |
Fiscal Year end for Vigil Neuroscience, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 22.48 | 21.42 | 23.85 | 22.33 | 21.91 |
Income After SG&A, R&D, and Dept/Amort Expenses | -22.48 | -21.42 | -23.85 | -22.33 | -21.91 |
Non-Operating Income | 1.25 | 1.48 | 1.68 | 1.83 | 1.74 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -21.23 | -19.94 | -22.17 | -20.50 | -20.17 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -21.23 | -19.94 | -22.17 | -20.50 | -20.17 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -21.23 | -19.94 | -22.17 | -20.50 | -20.17 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 40.57 | 39.86 | 38.83 | 38.81 | 38.66 |
Diluted EPS Before Non-Recurring Items | -0.52 | -0.50 | -0.57 | -0.53 | -0.52 |
Diluted Net EPS (GAAP) | -0.52 | -0.50 | -0.57 | -0.53 | -0.52 |